On October 8, 2026, a Phase 4 clinical trial involving teriparatide was listed with a status update of recruiting. The trial is titled "Combined Anabolic Therapy" and is registered under identifier NCT06558188. Teriparatide is an approved compound, and this study represents a Phase 4 trial, meaning it is being conducted after regulatory approval.
The trial's current status is recruiting, indicating that it is actively seeking participants as of the listed date. No results, outcomes, or efficacy data have been reported for this trial at this stage. The listing does not provide details on findings, safety signals, or comparative results, as the study has not reached that phase of reporting.
Readers should note that a recruiting status reflects only the operational stage of the trial, not any conclusions about the therapy being studied. Further updates would be expected as the trial progresses through subsequent phases, including completion and potential results reporting.
For more background on teriparatide, including its approved uses and general pharmacological profile, readers can consult the compound overview.